Predict your next investment

HEALTHCARE | Drug Development
verastem.com

See what CB Insights has to offer

Business Relationships

10

Service Providers

9

Verastem Service Providers

9 Service Providers

Verastem has 9 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

IPO

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

IPO

Subscribe to see more

Subscribe to see more

Provider Type

Accounting Firm

Subscribe to see more

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Partnership data by VentureSource

Verastem Partners & Customers

10 Partners and customers

Verastem has 10 strategic partners and customers. Verastem recently partnered with Mirati Therapeutics on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/22/2021

Partner

Mirati Therapeutics

United States

07:30 ET Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant ...

SAN DIEGO and BOSTON , Nov. 22 , 2021 / PRNewswire / -- Mirati Therapeutics , Inc. , a clinical-stage targeted oncology company and Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati Therapeutics , Inc. 's investigational KRASG12C inhibitor adagrasib with Verastem Oncology 's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer .

1

9/20/2021

Partner

Amgen

United States

Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM (Sotorasib) In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 , Verastem Oncology 's investigational dual RAF/MEK inhibitor , with Amgen 's KRAS inhibitor LUMAKRAS TM in KRAS G12C-mutant non-small cell lung cancer .

2

1/8/2020

Licensor

Chugai Pharmaceutical

Japan

Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co. Ltd. to Develop and Commercialize RAFMEK Inhibitor CH5126766

`` The exciting early clinical results led to our decision to enter into a partnership with Chugai for CH5126766 and accelerate the combination development program for patients with KRAS mutant cancers , which are highly aggressive and recurrent .

5

10/9/2019

Partner

Yakult Honsha

Japan

Subscribe to see more

Subscribe to see more

10

7/25/2019

Licensee

Sanofi

France

Subscribe to see more

Subscribe to see more

10

Date

11/22/2021

9/20/2021

1/8/2020

10/9/2019

7/25/2019

Type

Partner

Partner

Licensor

Partner

Licensee

Business Partner

Mirati Therapeutics

Amgen

Chugai Pharmaceutical

Yakult Honsha

Sanofi

Country

United States

United States

Japan

Japan

France

News Snippet

07:30 ET Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant ...

SAN DIEGO and BOSTON , Nov. 22 , 2021 / PRNewswire / -- Mirati Therapeutics , Inc. , a clinical-stage targeted oncology company and Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati Therapeutics , Inc. 's investigational KRASG12C inhibitor adagrasib with Verastem Oncology 's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer .

Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM (Sotorasib) In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 , Verastem Oncology 's investigational dual RAF/MEK inhibitor , with Amgen 's KRAS inhibitor LUMAKRAS TM in KRAS G12C-mutant non-small cell lung cancer .

Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co. Ltd. to Develop and Commercialize RAFMEK Inhibitor CH5126766

`` The exciting early clinical results led to our decision to enter into a partnership with Chugai for CH5126766 and accelerate the combination development program for patients with KRAS mutant cancers , which are highly aggressive and recurrent .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

5

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.